Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Expands By 121.8%

by · The Cerbat Gem

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) was the recipient of a significant growth in short interest in November. As of November 15th, there was short interest totalling 175,000 shares, a growth of 121.8% from the October 31st total of 78,900 shares. Based on an average daily trading volume, of 142,300 shares, the short-interest ratio is presently 1.2 days. Approximately 2.8% of the shares of the stock are sold short.

Adial Pharmaceuticals Trading Down 0.9 %

ADIL stock opened at $0.99 on Friday. Adial Pharmaceuticals has a 12-month low of $0.77 and a 12-month high of $4.17. The company has a 50 day moving average of $1.01 and a two-hundred day moving average of $1.09.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. RODMAN&RENSHAW upgraded shares of Adial Pharmaceuticals to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Adial Pharmaceuticals in a research note on Thursday, November 14th. They issued a “buy” rating and a $8.00 price objective for the company.

View Our Latest Research Report on Adial Pharmaceuticals

Institutional Investors Weigh In On Adial Pharmaceuticals

A hedge fund recently bought a new stake in Adial Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 20,469 shares of the company’s stock, valued at approximately $27,000. Virtu Financial LLC owned about 0.48% of Adial Pharmaceuticals at the end of the most recent quarter. Institutional investors own 16.41% of the company’s stock.

About Adial Pharmaceuticals

(Get Free Report)

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.

See Also